Brand Intelligence Graphcompany
Company Overview
About Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Business Model & Competitive Advantage
Pfizer's core commercial portfolio extends across oncology, rare disease, internal medicine, and vaccines. Eliquis (apixaban, co-promoted with Bristol-Myers Squibb) remains the world's best-selling anticoagulant; Ibrance leads in CDK4/6 inhibitor breast cancer therapy; Vyndaqel/Vyndamax dominates the ATTR-CM (transthyretin cardiomyopathy) market where it has achieved blockbuster status. The Prevnar pneumococcal vaccine franchise and Nimenrix meningococcal vaccines anchor a diversified global vaccine portfolio. Pfizer's "Fit-to-Win" restructuring program targets $4 billion in annual cost savings by 2025, realigning R&D investments toward the highest-value pipeline opportunities post-Seagen integration.
Competitive Landscape 2025–2026
In 2025-2026, Pfizer confronts significant patent cliff risks: Eliquis faces generic competition beginning in 2026-2028, representing roughly $7 billion in annual U.S. revenues at risk. The Seagen ADC platform is the primary offense against this cliff, with Padcev already generating $1 billion-plus in annual revenues for metastatic urothelial cancer. Competitive pressures come from AstraZeneca (Enhertu in ADCs), Eli Lilly (oncology expansion), and Merck (Keytruda franchise). Activist investor Starboard Value took a stake in late 2024 and has pressed for more aggressive cost cuts and strategic review. Pfizer's GLP-1 obesity drug danuglipron failed Phase 2 trials in 2023, leaving the company without a direct entry in the fast-growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk.
The Pfizer Story
Founders
Recent Activity
View all →Oblenio Bio riverh29 Thu, 08/13/2026 - 13:00 Active Portfolio Companies Oblenio Bio is a clinical-stage company pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through its LBL-051 T cell engager. Specifically engineered for autoimmune patients, this tri-specific unites validated targets BCMA, CD19 and CD3 to safely and completely deplete B cells and plasma cells to achieve long-term drug-free remission. The company is singularly focused on LBL-051’s innovative clinical development program to rapidly establish it as a life-changing treatment for the vast number of patients who endure severe autoimmune disease without relief. Lexington, MA visit www.obleniobio.com
An Interventional, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants zhoum55 Wed, 08/12/2026 - 22:42 Nurtec® Rimegepant (PF-07899801, BHV-3000) PHASE III Mon, 05/15/2023 - 12:00 Wed, 12/10/2025 - 12:00 NCT05810038 C4951019 Public Disclosure Synopsis.pdf (137.13 KB) N https://clinicaltrials.gov/study/NCT05810038?term=C4951019&viewType=Card&rank=1 BHV3000-319 (C4951019)
Material Event filed 2026-08-04
Quarterly Report filed 2026-08-04
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS secchiarolim Wed, 07/15/2026 - 14:08 PF-07926307 (Combination COVID-19 and Influenza modRNA Vaccine) PHASE I/II Mon, 11/11/2024 - 12:00 Tue, 07/15/2025 - 12:00 NCT06683352 C5261023 Public Disclosure Synopsis.pdf (102.04 KB) N https://clinicaltrials.gov/study/NCT06683352?term=C5261023&viewType=Table&rank=1 C5261023
An Interventional, Open-Label, Randomized, Multicenter, Phase 2 Study of PF-07220060 Plus Letrozole Compared to Letrozole Alone in Postmenopausal Women 18 Years or Older With Hormone Receptor-Positive, HER2-Negative Breast Cancer in The Neoadjuvant Settin soansm01 Fri, 06/26/2026 - 04:52 PF-07220060 PF-07220060 PHASE II Thu, 07/11/2024 - 12:00 Thu, 07/10/2025 - 12:00 NCT06465368 C4391025 Public Disclosure Synopsis .pdf (127.11 KB) N https://clinicaltrials.gov/study/NCT06465368?term=%20C4391025&viewType=Card&rank=1 C4391025
Material Event filed 2026-06-18
Material Event filed 2026-06-18
Final Report: A Phase 3, Randomized, Double- Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Pregnant Participants Living with HIV and Their Inf chavak11 Wed, 06/10/2026 - 06:28 Abrysvo PF-06928316 PHASE III Tue, 03/12/2024 - 12:00 Wed, 06/11/2025 - 12:00 NCT06325657 C3671032 Public Disclosure Synopsis .pdf (151.7 KB) N https://clinicaltrials.gov/study/NCT06325657?term=C3671032&viewType=Card&rank=1 C3671032
A Phase 4, Randomized, Double-Blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use soansm01 Wed, 06/10/2026 - 02:23 Nurtec® ODT Rimegepant PHASE IV Tue, 10/18/2022 - 12:00 Tue, 06/10/2025 - 12:00 NCT05509400 C4951004 (BHV3000-406) Public Disclosure Synopsis.pdf (169.82 KB) N https://clinicaltrials.gov/study/NCT05509400?term=C4951004%20&viewType=Card&rank=1 C4951004 (BHV3000-406)
C5041006 sub study 4 amsdenmb Mon, 06/08/2026 - 16:39 Velsipity etrasimod PHASE II/III Mon, 01/06/2020 - 12:00 Mon, 06/09/2025 - 12:00 NCT04173273 C5041006 SS4 Public Disclosure Synopsis.pdf (105.28 KB) N https://clinicaltrials.gov/study/NCT04173273?term=c5041006&viewType=Card&rank=1 C5041006 sub study 4
C5041006 sub study 3 amsdenmb Mon, 06/08/2026 - 16:21 Velsipity etrasimod PHASE II/III Mon, 01/06/2020 - 12:00 Mon, 06/09/2025 - 12:00 NCT04173273 C5041006 SS3 Public Disclosure Synopsis.pdf (160.8 KB) N https://clinicaltrials.gov/study/NCT04173273?term=c5041006&viewType=Card&rank=1 C5041006 sub study 3
Company Timeline
Major milestones in Pfizer's journey
Leadership Team
Meet the leaders behind Pfizer
Dr. Albert Bourla
Albert Bourla is a Greek-American veterinarian and businessman who became CEO of Pfizer in January 2019 and Chairman in February 2019. During his 30+ years at Pfizer, he held senior management positions across five countries and established Pfizer's Purpose Blueprint with core values of Courage, Excellence, Equity, and Joy to create a culture where science and people thrive.
David M. Denton
Dave Denton joined Pfizer as CFO and Executive Vice President effective May 2, 2022, providing strategic global financial leadership as a member of Pfizer's Executive Leadership Team. He oversees all financial operations and strategy for the company.
Dr. Chris Boshoff
Chris Boshoff, M.D., PhD, was appointed Chief Scientific Officer and President of Research & Development effective January 1, 2025, following a comprehensive selection process. Previously Chief Oncology Research and Development Officer, he leads Pfizer's global R&D efforts and scientific strategy.
Aamir Malik
Aamir Malik is Executive Vice President and Chief U.S. Commercial Officer, leading the U.S. Commercial business including Primary and Specialty Care Commercial and Medical Affairs, Oncology Commercial, Global Access and Value, and Global Chief Marketing Office organizations as a member of the Executive Leadership Team.
Dr. Andrew Baum
Andrew Baum, M.D., joined Pfizer as Chief Strategy and Innovation Officer and Executive Vice President, reporting to CEO Dr. Albert Bourla. He is a member of Pfizer's Executive Leadership Team responsible for corporate strategy and innovation initiatives.
Key Differentiators
Market Leader
Pfizer is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $63.6B in revenue, Pfizer operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Pfizer with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Pfizer? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Pfizer Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pfizer vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →